<DOC>
	<DOCNO>NCT00021099</DOCNO>
	<brief_summary>Phase II trial study effectiveness ixabepilone treat patient progressive metastatic urinary tract cancer . Drugs use chemotherapy use different way stop tumor cell divide stop growing die</brief_summary>
	<brief_title>Ixabepilone Treating Patients With Advanced Urinary Tract Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate patient advance carcinoma urothelium treat ixabepilone . II . Assess toxicity drug patient . OUTLINE : Patients stratify accord prior treatment taxanes ( yes v ) . Patients receive ixabepilone IV 3 hour day 1 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year every 6 month 1 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<criteria>Histologically confirm transitional cell carcinoma ( TCC ) urothelium ( renal pelvis , ureter , bladder , urethra ) Mixed histology carcinoma TCC component allow Progressive regional disease Metastatic disease Failed 1 1 prior systemic chemotherapy regimen contain cisplatin carboplatin adjuvant , neoadjuvant , metastatic setting May include taxanebased therapy Measurable disease outside prior irradiation field Previously resect irradiated CNS metastases evidence stable disease allow Performance status ECOG 02 Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin great 1.5 mg/dL AST great 2.5 time upper limit normal Creatinine great 1.5 mg/dL No prior severe cardiovascular disease ( American Heart Association class III IV heart disease ) No uncontrolled congestive heart failure No ventricular dysrhythmia No active unresolved infection require parenteral antibiotic within past week No malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer , carcinoma situ cervix , clinically unsuspected organconfined prostate cancer treat prior prostatectomy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior systemic biologic response modifier therapy See Disease Characteristics At least 4 week since prior chemotherapy recover See Disease Characteristics At least 4 week since prior radiotherapy recover No concurrent radiotherapy See Disease Characteristics At least 4 week since prior major surgery recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>